



Ahmed Salim¹, Ihsan AlSaimary¹, Amal Adil Kasid Alsudany², Ahmed Salih Hussien Alshewered^{3,4}✉

¹ College of Medicine, University of Basrah, Basrah, Iraq

² Basrah Health Directorate, Ministry of Health, Basrah, Iraq

³ Misan Radiation Oncology Center, Misan, Iraq

⁴ Misan Health Directorate, Ministry of Health/Environment, Misan, Iraq

Recording the New Genes for CCL2, CCL5 and CXCL10 Chemokines in Cases with Neuroinflammation and Multiple Sclerosis: A Brief Report

Conflict of interest: nothing to declare.

Authors' contribution: Ahmed Salim – conceptualization, data curation, investigation, methodology, project administration, resources, software, writing – original draft and editing; Ihsan AlSaimary – conceptualization, data curation, methodology, resources, writing – original draft and editing; Amal Alsudany – conceptualization, data curation, investigation, methodology, writing – original draft and editing; Ahmed Alshewered – conceptualization, data curation, investigation, methodology, resources, software, writing – original draft and editing.

The article is published in author's edition.

Submitted: 15.04.2025

Accepted: 12.08.2025

Contacts: ahmedsalihdr2008@yahoo.com

Abstract

Purpose. To discover new genes for CCL2, CCL5, and CXCL10 in patients with neuroinflammation and multiple sclerosis.

Materials and methods. The equipment and instruments used in this study with biological materials and chemicals used were from different countries and origins. The registered in NCBI under the accession of the GeneBank.

Results. New genes for CCL2, CCL5 and CXCL10 chemokines were identified, which were (LC727557), (LC727558) and (LC727558) respectively.

Keywords: multiple sclerosis, inflammatory neurological disease, CCL2, CCL5, CXCL10



Ахмед Салим¹, Ихсан АльСаймари¹, Амаль Адил Касид Альсудани², Ахмед Салих Хуссейн Альшеверед^{3,4}✉

¹ Колледж медицины, Университет Басры, Басра, Ирак

² Управление здравоохранения Басры, Министерство здравоохранения, Басра, Ирак

³ Центр радиационной онкологии Мисана, Мисан, Ирак

⁴ Управление здравоохранения Мисана, Министерство здравоохранения и окружающей среды, Мисан, Ирак

Выявление новых генов хемокинов CCL2, CCL5 и CXCL10 у пациентов с нейровоспалением и рассеянным склерозом: краткое сообщение

Конфликт интересов: не заявлен.

Вклад авторов: Ахмед Салим – концепция, обработка данных, проведение исследований, методология, ведение проекта, ресурсы, написание чернового варианта статьи, редактирование; Ихсан АльСаймари – концепция, обработка данных, методология, ресурсы, написание чернового варианта статьи, редактирование; Амаль Альсудани – концепция, обработка данных, методология, ресурсы, проверка подлинности полученных данных, написание чернового варианта статьи, редактирование; Ахмед Альшеверед – концепция, обработка данных, методология, ресурсы, программное обеспечение, написание чернового варианта статьи, редактирование.

Статья опубликована в авторской редакции.

Подана: 15.04.2025

Принята: 12.08.2025

Контакты: ahmedsalihdr2008@yahoo.com

Резюме

Цель. Выявление новых генов CCL2, CCL5 и CXCL10 у пациентов с нейровоспалением и рассеянным склерозом.

Материалы и методы. Оборудование и инструменты, использованные в данном исследовании, а также биологические материалы и химические вещества получены от разных производителей из разных стран. Результаты зарегистрированы в Национальном центре биотехнологической информации (NCBI) в разделе GeneBank.

Результаты. В результате исследования были идентифицированы новые гены хемокинов CCL2, CCL5 и CXCL10, получившие обозначения LC727557, LC727558 и LC727558 соответственно.

Ключевые слова: рассеянный склероз, воспалительное неврологическое заболевание, CCL2, CCL5, CXCL10

■ INTRODUCTION

Chemokines (chemoattractant cytokines) are small basic proteins (large group) with a molecular weight between (8–14 kDa) and are featured by attract leukocytes to the site of inflammation and infection [1].

Monocyte-derived neutrophil chemotactic factor (MDNCF), first discovered by Yoshimura et al. in 1987 [2]. Currently, this group has been extensively studied, and more than 50 different chemokines have been recorded in human [3–6].

CCL2 (Monocyte Chemoattractant Protein-1): This chemokine is involved in recruiting monocytes to sites of inflammation. In MS, it plays a role in the migration of immune cells into the central nervous system (CNS), contributing to the inflammatory response. CCL5 (RANTES – Regulated upon Activation, Normal T cell Expressed, and Secreted): CCL5 is important in the recruitment of T cells, eosinophils, and basophils to inflammatory sites. Elevated levels are often observed in MS and other inflammatory diseases. CXCL10 (IP-10 – Interferon gamma-induced protein 10): This chemokine is strongly associated with Th1 responses and is involved in the attraction of T cells to inflammatory sites. CXCL10 is considered a critical factor in the pathogenesis of MS [7–9]. They play a role in immune regulation and T-cell polarization, induction of respiratory bursts, apoptosis, angiogenesis, mitosis, tumor metastasis, wound healing, and secretion of cytokines and extracellular matrix proteases. The main focus of MS chemokines is to gain further insight into lesion evolution, disease pathogenesis, and identification of potential therapeutic targets. However, definitive attributions of the pathogenic role of chemokines and receptors in human CNS diseases remain challenging [7]. Based on the knowledge about the diagnostic role of various chemokines that contribute to multiple sclerosis and the dynamic mechanism for its role in the early diagnosis, it was hypothesized that: Is a specific chemokine related to the pathogenesis of multiple sclerosis in Iraq, such as the presence of chemokines CCL2, CCL5, and CXCL10.

■ PURPOSE OF THE STUDY

To discover new genes for CCL2, CCL5, and CXCL10 in patients with neuroinflammation and multiple sclerosis.

■ MATERIALS AND METHODS

The equipment and instruments used in this study are listed in table 1.

The biological materials and chemicals used are listed in table 2.

Table 1
The equipment's and instruments used in the study

| Item | Description and Company | Country |
|-----------------------------------|-----------------------------|-----------|
| Butterfly Syringe | IMPROVE | China |
| EDTA tube | APCO | Jordan |
| Gel tube | Gongdong | China |
| Cold rack box | Biobasic | U.K. |
| Disposable glove | Care gloves | Malaysia |
| Centrifuge | NUVE | Turkey |
| Eppendorf Tube | 1.5 ml, ABDOS | India |
| Disposable tips | 20, 200, 1000 ml, Citotest | China |
| Micropipette | 10–1000, Biobase | Germany |
| Horizontal electrophoresis system | Mupid-One | Japan |
| Gradient Thermal Cycler | T100 Thermal Cycler, BioRad | Singapore |
| Microcentrifuge | Mikro 120, Hettich | Germany |
| Vortex mixer | LVM-202, DAIHAN | Korea |
| Water Bath | LWB-111D, DAIHAN LabTech | Korea |
| Elisa Reader | Mindray | China |
| Distilled water | Alab Tech | Korea |
| Incubator | Memmert | Germany |
| Microwave Oven | Panasonic | Japan |



Table 2
The chemical and already prepared solution

| Item | Description and Company | Country |
|---|---|------------|
| 1500pb DNA ladder | Lot: 1101C, Cat. No. D-1030, Volume 250 μ l, Concentration 135ng/ μ l. Bioneer | Korea |
| 10x TBE (Tris-Borate-EDTA) buffer 1 liter bottle | Bio Basic Inc. | Canada |
| Ethanol | J.K. Baker | Netherland |
| Agarose | Bio Basic Inc. | Canada |
| Bromophenol blue | Bio Basic Inc. | Canada |
| Ethidium bromide (10 mg/ml Solution) | Bio Basic Inc. | Canada |
| Nuclease free water | Bioneer | Korea |

Ethics Statement

This study was approved by the IRB committee of the Research Units, Training and Humanity Development Center, Basrah Health Directorate, and Department of Medicine, University of Basrah/Researches Units, Training and Humanity Development Center, Basrah Health Directorate (No.109/2021 [479] on 17/11/2021 and No. 855 on 21/11/2021).

■ RESULTS

The newly identified genes are shown in figure 1, 2 and 3. The new genes for CCL2, CCL5 and CXCL10 chemokines were recorded, and the results were registered in NCBI under the accession numbers (LC727557), (LC727558) and (LC727558) respectively.

■ DISCUSSION

Depending on the no. and spacing of cysteine residues included in the formation of disulfide bonds, the chemokines are categorized into 5 groups, which are: C-C (β -chemokine), C-X-C (α -chemokine), X-C (δ -chemokine (C-subfamily)), C-X-3-C (γ -chemokine) and C-X chemokines [8–10].

The chemokines of C-C, C-X-C, and C-X-3-C families have 4 cysteines, X-C chemokines only have 2. C-C chemokines are the largest group containing two adjacent cysteine residues near their N-terminus, and genes are grouped on chromosome-17 in human [4–6].

In the C-X-3-C and C-X-C chemokine subfamilies, there are 1 to 3 additional amino acids (represented 3X or X) separate the 1st two of the four cysteine residues, and most of the C-X-C chemokines are clustered on chromosome-4 in humans. The 5th sub-family C-X chemokine, which was recently identified in zebra-fish by Nomiya in 2008, lacks one of the two N-terminal cysteine residues, but retain the 3rd and 4th [2, 10].

These new genes cannot be compared with other studies because no data were found in the literature.

Clinical Relevance

Play an important roles as prognostic biomarkers: The expression levels of chemokines in blood or CSF may serve as biomarkers for disease activity or progression in MS. In addition, the roles as therapeutic targets: Chemokine inhibitors or blockers targeting

GenBank

Send to:

Homo sapiens CCL2 gene for C-C motif chemokine ligand 2, partial sequence

GenBank: LC727557.1

FASTA Graphics

Go to:

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

FEATURES

source

gene

misc_feature

ORIGIN

LC727557

Homo sapiens CCL2 gene for C-C motif chemokine ligand 2, partial sequence.

LC727557

LC727557.1

.

Homo sapiens (human)

Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo.

1

Amal,A.K., Ihsan,E.A. and Ahmed,A.S.

Immunopathogenesis, molecular determination and neuro inflammatory role of ccl2, ccl5 and cxcl10 chemokines among patients with multiple sclerosis

Unpublished

2 (bases 1 to 442)

Kasid,A.A., Ihsan,E.A. and Ahmed,A.S.

Direct Submission

Submitted (03-SEP-2022) Contact:Amal Adil Kasid Ministry of Higher Education and Scientific Research, University of Basra, College of Medicine, Microbiology; The Schools Street, Hay AL Hussain, Basrah, Iraq

Location/Qualifiers

1..442

/organism="Homo sapiens"

/mol_type="genomic DNA"

/db_xref="taxon:9606"

/chromosome="17"

/map="17q12"

/country="Iraq"

/collection_date="2022-01-17"

/PCR_primers="fwd_seq: agaatcaccagcagcaagtgtcc, rev_seq: tcctgaaccacttctgcttgg"

<1..>442

/gene="CCL2"

<1..>442

/gene="CCL2"

/note="C-C motif chemokine ligand 2; contains intron and exon"

1 atctggttca gccaccaacc ttccctggcc tgaagttctt ccttgtggag caagggacaa

61 gcctcataaa ctagagtica gagagtgcac tatttaactt aatgtacaaa ggttcccaat

121 gggaaaactg aggcaccaag ggaaaaagtg aacccaaca tcactctcca cctgggtgcc

181 tattcagaac accccaattt cttagccttg aagtcaggat ggctccacct ggacacctat

241 aggagcagtt tgccctgggt tccctccttc cacctgcgtt cctcctctag ctcccatggc

301 agcccttgg ggcagaatgg gctgcacttc tagaccaaaa ctgcaaagga acttcattca

361 actctgtcct cctctcccac agcttcaaga ccatttgtgc caaggagatc tgtgtctgacc

421 ccaagcgaa tggggttcag ga

//

Fig. 1. Homo sapiens CCL2 gene for C-C motif chemokine ligand 2

486

"Neurology and Neurosurgery Eastern Europe", 2025, volume 15, No. 3



GenBank ▾

Send to: ▾

Homo sapiens CCL5 gene for C-C motif chemokine ligand 5, intron 1, partial sequence

GenBank: LC727558.1

[FASTA](#) [Graphics](#)[Go to:](#) ☒

LOCUS LC727558 449 bp DNA linear PRI 08-SEP-2022
DEFINITION Homo sapiens CCL5 gene for C-C motif chemokine ligand 5, intron 1, partial sequence.
ACCESSION LC727558
VERSION LC727558.1
KEYWORDS .
SOURCE Homo sapiens (human)
ORGANISM [Homo sapiens](#)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Amal,A.K., Ihsan,E.A. and Ahmed,A.S.
TITLE Immunopathogenesis, molecular determination and neuro inflammatory role of ccl2, ccl5 and cxcl10 chemokines among patients with multiple sclerosis
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 449)
AUTHORS Kasid,A.A., Ihsan,E.A. and Ahmed,A.S.
TITLE Direct Submission
JOURNAL Submitted (03-SEP-2022) Contact:Amal Adil Kasid Ministry of Higher Education and Scientific Research, University of Basra, College of Medicine, Microbiology; The Schools Street, Hay AL Hussain, Basrah, Iraq
FEATURES
source Location/Qualifiers
1..449
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/chromosome="17"
/map="17q12"
/country="Iraq"
/collection_date="2022-12-01"
/PCR_primers="fwd_seq: acacttgacattgtgctggac, rev_seq: agtggcaactgatgcttccc"
gene <1..>449
/gene="CCL5"
intron <1..>449
/gene="CCL5"
/note="C-C motif chemokine ligand 5"
/number=1
ORIGIN
1 ttgaattaac tgacaacaag aagtctctctg ttgagagccc ttctcactga agctcaacca
61 gagctcccaa gatacaatat gcatctccag gcccttctta ggatcctggc tgagtcattg
121 agcctgagct ttggaagcct cccacaacc tgccctaggt ctcaagaaga ccaagttcca
181 aatcctttga ggaatgctgga agggcaagaa tgaagccaga ggaccaggga caagccaggga
241 ggaggccctg aaagccagg gcagaaggtt atggtgtaga gggatggata caagcttgcc
301 tcaaggatta gatgagcat tggaaacccc actctgccac tgtttatcca tggccaagtg
361 actttacctc tctgagcctc agtttctgtc aaggaagata acagttcttt ctaaataaat
421 catataaagt gtccagcaat gtcccaagt
//

Fig. 2. Homo sapiens CCL5 gene for C-C motif chemokine ligand 5

GenBank

Send to:

Homo sapiens CXCL10 gene for C-X-C motif chemokine ligand 10, partial sequence

GenBank: LC727559.1

[FASTA](#) [Graphics](#)

Go to:

LOCUS

LC727559

273 bp

DNA

linear

PRI 08-SEP-2022

DEFINITION

Homo sapiens CXCL10 gene for C-X-C motif chemokine ligand 10, partial sequence.

ACCESSION

LC727559

VERSION

LC727559.1

KEYWORDS

.

SOURCE

Homo sapiens (human)

ORGANISM

Homo sapiens

REFERENCE

1

AUTHORS

Amal,A.K., Ihsan,E.A. and Ahmed,A.S.

TITLE

Immunopathogenesis, molecular determination and neuro inflammatory role of ccl2, ccl5 and cxcl10 chemokines among patients with multiple sclerosis

JOURNAL

Unpublished

REFERENCE

2 (bases 1 to 273)

AUTHORS

Kasid,A.A., Ihsan,E.A. and Ahmed,A.S.

TITLE

Direct Submission

JOURNAL

Submitted (03-SEP-2022) Contact:Amal Adil Kasid Ministry of Higher Education and Scientific Research, University of Basra, College of Medicine, Microbiology; The Schools Street, Hay AL Hussain, Basrah, Iraq

FEATURES

Location/Qualifiers

source

1..273

/organism="Homo sapiens"

/mol_type="genomic DNA"

/db_xref="taxon:9606"

/country="Iraq"

/collection_date="2021-12-05"

/PCR_primers="fwd_seq: ccaattttgtccacgtgttg, rev_seq: ttcttgatggccttcgattc"

gene

<1..>273

/gene="CXCL10"

misc_feature

<1..>273

/gene="CXCL10"

/note="C-X-C motif chemokine ligand 10; contains intron and exon"

ORIGIN

1 aattttgtcc acgtgttgag atcatgtgag tgaatccca tctgattatc acttccctgg

61 ttgtaattat atactgtatt aaatatgtaa tgataataaa aaagatcagt aaagggtttg

121 tgatgattct aaaactaatg tacagcaaac aaaaacatgc agagtgaac ttaaatgtct

181 gacttcagaa ttgcgtatgc catctgtttt attgacccaa cacagtttta aatatattca

241 tccctattta ttctacagt gtacaagaa aaa

//

Fig. 3. Homo sapiens CXCL10 gene for C-X-C motif chemokine ligand 10

receptors for CCL2, CCL5, or CXCL10 might offer therapeutic potential. Drugs like Plerixafor (CXCR4 antagonist) or Efalizumab (anti-CD11a, involved in T cell trafficking) have been explored, but their impact on these specific chemokines needs further investigation.

488

"Neurology and Neurosurgery Eastern Europe", 2025, volume 15, No. 3



Clinical Implications

- Increased Expression of CCL2, CCL5, and CXCL10 in MS Patients: These chemokines may be up-regulated during MS relapse and inflammation, and their levels may correlate with disease severity.
- Therapeutic Targeting: Identifying the role of each chemokine can help develop targeted treatments that modulate the immune response in MS.

Future Recommendations

It might be used in gene expression in MS, genetic variants in MS and chemokine genes and experimental models:

- Tissue Samples: Gene expression levels of CCL2, CCL5, and CXCL10 should be measured in relevant tissues. This can include blood samples (for peripheral immune markers) and cerebrospinal fluid (CSF) or brain tissues (in postmortem MS cases or animal models of MS).
- Real-Time PCR (RT-PCR): One of the most common techniques to quantify gene expression levels. Specific primers for CCL2, CCL5, and CXCL10 can be used to amplify mRNA from samples.
- Western Blotting/ELISA: These methods can be used to measure the protein levels of these chemokines, providing insight into the regulation at the protein level.
- Flow Cytometry: Can be used for analyzing immune cells in circulation and within the CNS that may express chemokine receptors, correlating with the levels of these chemokines.
- Single-Nucleotide Polymorphisms (SNPs): Research has shown that certain genetic variations in the promoters or coding regions of chemokine genes may influence the progression of MS. For example, SNPs in the CCL2 gene could lead to increased expression of the chemokine.
- GWAS (Genome-Wide Association Studies): Genetic studies may reveal associations between variants in CCL2, CCL5, and CXCL10 genes and susceptibility to MS or disease progression.
- Epigenetic Modifications: DNA methylation and histone modification patterns in the promoter regions of these chemokine genes might also play a role in their expression during neuroinflammation.
- EAE (Experimental Autoimmune Encephalomyelitis): This animal model is often used to study MS. Measurement of chemokine expression in EAE models can help understand the role of these chemokines in the development of neuroinflammation and demyelination.
- Humanized MS Models: These models mimic human immune responses and may provide additional insights into how chemokines like CCL2, CCL5, and CXCL10 contribute to MS pathogenesis.

CONCLUSION

New genes for ccl2, ccl5 and cxcl10 chemokines were recorded, and the results are registered in NCBI under accession numbers (LC727557), (LC727558) and (LC727558) respectively. In addition, the understanding the role of CCL2, CCL5, and CXCL10 in neuroinflammation within MS is crucial for identifying potential therapeutic targets.

Their gene expression and associated SNPs in MS patients can contribute to better diagnostics and treatment strategies, potentially slowing disease progression or improving clinical outcomes.

■ REFERENCES

1. Hassanshahi G, Jafarzadeh A, James Dickson A. Expression of stromal derived factor alpha (SDF-1 alpha) by primary hepatocytes following isolation and heat shock stimulation. *Iran J Allergy Asthma Immunol.* 2008;7(2):61–8.
2. Cheng W, Chen G. Chemokines and chemokine receptors in multiple sclerosis. *Mediators Inflamm.* 2014;2014:659206.
3. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. *N Engl J Med.* 2006;354(6):610–21.
4. Ruder J, Dinner G, Maceski A, et al. Dynamics of Inflammatory and Neurodegenerative Biomarkers after Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. *Int J Mol Sci.* 2022;23(18):10946.
5. Ghafouri-Fard S, Honarmand K, Taheri M. A comprehensive review on the role of chemokines in the pathogenesis of multiple sclerosis. *Metab Brain Dis.* 2021;36(3):375–406.
6. Cui LY, Chu SF, Chen NH. The role of chemokines and chemokine receptors in multiple sclerosis. *Int Immunopharmacol.* 2020;83:106314.
7. Mackay CR. Chemokines: immunology's high impact factors. *Nat Immunol.* 2001 Feb;2(2):95–101.
8. Nomiya H, Osada N, Yoshie O. The evolution of mammalian chemokine genes. *Cytokine Growth Factor Rev.* 2010;21(4):253–62.
9. Xu H, Lin S, Zhou Z, Li D, et al. New genetic and epigenetic insights into the chemokine system: the latest discoveries aiding progression toward precision medicine. *Cell Mol Immunol.* 2023;20(7):739–776.
10. Elemam NM, Talaat IM, Maghazachi AA. CXCL10 Chemokine: A Critical Player in RNA and DNA Viral Infections. *Viruses.* 2022;14(11):2445.